WT1 and melanoma: As DCP-001 is generated from the myeloid leukemic cell line DCOne, it endogenously expresses multiple undefined and defined TAAs, such as the shared TAAs Wilms’ tumor-1 (WT-1), preferentially expressed antigen in melanoma (PRAME), receptor for hyaluronan-mediated motility (RHAMM), mucin-1 (MUC-1) and survivin, that are all proven to be valid targets for the immune system in both acute myeloid leukemia (AML) as well as several other cancer types, including solid tumors, such as ovarian cancer [4,5,6].